

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 596704064 US, on the date shown below in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: March 26, 2007


Signature:



(Lori Sims)

Patent

Docket No. 282172000602


MAR 26 2007
PATENT & TRADEMARK OFFICE
U.S. PATENT AND TRADEMARK OFFICE
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
David COOK et al.

Serial No.: 10/803,109

Filing Date: March 17, 2004

For: METHODS FOR QUENCHING
PATHOGEN INACTIVATORS IN
BIOLOGICAL MATERIALS

Examiner: S. Saucier

Group Art Unit: 1651

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of the documents other than the U.S. patent document are also submitted herewith. The Examiner is requested to make these documents of record.

This Supplemental Information Disclosure Statement is submitted:

- With the application; accordingly, no fee or separate requirements are required.
- Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.

03/29/2007 HVUDNG1 00000044 031952 10803109

03 FC:1806 180.00 DA

pa-1124636

- Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - A fee is required. A check in the amount of __ is enclosed.
 - A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is believed to be due.
- After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of __ is enclosed.
 - A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.

Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petition and/or other

Application Serial No. 10/803,109


Patent
Docket No. 282172000602

fees due in connection with the filing of this document to **Deposit Account No. 03-1952**
referencing 282172000602.


Dated: March 26, 2007

Respectfully submitted,

By


Alicia J. Hager
Registration No.: 44,140

MORRISON & FOERSTER LLP
755 Page Mill Road
Palo Alto, California 94304-1018
(650) 813-4296



Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

				Complete if Known	
				Application Number	10/803,109
				Filing Date	March 17, 2004
				First Named Inventor	David COOK
				Art Unit	1651
				Examiner Name	S. Saucier
Sheet	1	of	1	Attorney Docket Number	282172000602

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
1.	US-2006-0115466-A1		06-01-2006	Stassinopoulos	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
2.	WO-96/40857-A1		12-19-1996	Steritech, Inc.		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
3.	Al-Harbi, M.M. et al. (1997). "Gentamycin and Cyclosporine Increase Total Soluble Thiols in the Plasma and Lymphocytes of Rats and Perturb Erythrocyte Fragility," <i>Med. Sci. Res.</i> 25:155-157.		
4.	Awasthi, Y.C. et al. (December 28, 1984). "Purification and Characterization of a New Form of Glutathione S-Transferase from Human Erythrocytes," <i>Biochemical and Biophys. Res. Commun.</i> 125(3):1053-1060.		
5.	Högman, C.F. et al. (March 1993). "Half-Strength Citrate CPD Combined with a New Additive Solution for Improved Storage of Red Blood Cells Suitable for Clinical Use," <i>Vox Sang</i> 65:271-278.		
6.	Petz, L.D. et al., eds. (1996). " γ Irradiation of Cellular Blood Components for Prevention of TA-GVHD," In "Graft-Versus-Host-Disease" In <i>Clinical Practice of Transfusion Medicine</i> , Third Edition, Churchill Livingstone, pp. 939-940.		
7.	Song, P.-S. et al. (June 1979). "Review Article: Photochemistry and Photobiology of Psoralens," <i>Photochem. and Photobio.</i> 29:1177-1197.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered
--------------------	--	-----------------